

# DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

August 2009

Vol. 37, No. 8

## CONTENTS

### MINIREVIEW

- The Ontogeny, Distribution, and Regulation of Alcohol Dehydrogenase 3: Implications for Pulmonary Physiology. *Chad M. Thompson, Babasaheb Sonawane, and Roland C. Grafström* . . . . . **1565**

### SHORT COMMUNICATIONS

- Binding of Lopinavir to Human  $\alpha_1$ -Acid Glycoprotein and Serum Albumin. *Abhishek Gulati, F. Douglas Boudinot, and Phillip M. Gerk* . . . . . **1572**

- The Glycogen Synthase Kinase Inhibitor 3-(2,4-Dichlorophenyl)-4-(1-methyl-1*H*-indol-3-yl)-1*H*-pyrrole-2,5-dione (SB216763) Is a Partial Agonist of the Aryl Hydrocarbon Receptor. *Albert Braeuning and Albrecht Buchmann* . . . . . **1576**

- Glycerolysis of Acyl Glucuronides as an Artifact of in Vitro Drug Metabolism Incubations. *R. Scott Obach* . . . . . **1581**

### ARTICLES

- Semiphysiologically Based Pharmacokinetic Models for the Inhibition of Midazolam Clearance by Diltiazem and Its Major Metabolite. *Xin Zhang, Sara K. Quinney, J. Christopher Gorski, David R. Jones, and Stephen D. Hall* . . . . . **1587**

- Evaluation of Luciferin-Isopropyl Acetal as a CYP3A4 Substrate for Human Hepatocytes: Effects of Organic Solvents, Cytochrome P450 (P450) Inhibitors, and P450 Inducers. *Albert P. Li* . . . . . **1598**

- Involvement of Vitamin D Receptor in the Intestinal Induction of Human ABCB1. *Shuko Tachibana, Kouichi Yoshinari, Tsubasa Chikada, Takayoshi Toriyabe, Kiyoshi Nagata, and Yasushi Yamazoe* . . . . . **1604**

- [S]** Rifampicin-Activated Human Pregnane X Receptor and CYP3A4 Induction Enhance Acetaminophen-Induced Toxicity. *Jie Cheng, Xiaochao Ma, Kristopher W. Krausz, Jeffrey R. Idle, and Frank J. Gonzalez* . . . . . **1611**

- Disposition and Metabolism of a Novel Prostanoid Antiglaucoma Medication, Tafluprost, Following Ocular Administration to Rats. *Y. Fukano and K. Kawazu* . . . . . **1622**

- Disposition and Metabolism of Radiolabeled Casopitant in Humans. *Mario Pellegatti, Ellenia Bordini, Patrizia Fizzotti, Andy Roberts, and Brendan M. Johnson* . . . . . **1635**

- Identification of Human Metabolites of  $(-)$ -*N*-{2-[*(R*)-3-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a Novel If Channel Inhibitor, and Investigation of the Transporter-Mediated Renal and Hepatic Excretion of These Metabolites. *Ken-ichi Umebara, Nobuaki Shirai, Takafumi Iwatsubo, Kiyoshi Noguchi, Takashi Usui, and Hidetaka Kamimura* . . . . . **1646**

- [S]** Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction. *Odette A. Fahmi, Susan Hurst, David Plowchalk, Jack Cook, Feng Guo, Kuresh Youdim, Maurice Dickens, Alex Phipps, Amanda Darekar, Ruth Hyland, and R. Scott Obach* . . . . . **1658**

- Further Assessment of 17*α*-Ethinyl Estradiol as an Inhibitor of Different Human Cytochrome P450 Forms in Vitro. *Shu-Ying Chang, Cliff Chen, Zheng Yang, and A. David Rodrigues* . . . . . **1667**

Continued on next page

Downloaded from dmd.aspetjournals.org at ASPET Journals on March 13, 2024

Contents (cont'd.)

- Oseltamivir (Tamiflu) Is a Substrate of Peptide Transporter 1. *Takuo Ogihara, Takashi Kano, Tamae Wagatsuma, Sho Wada, Hikaru Yabuuchi, Shigeki Enomoto, Kaori Morimoto, Yoshiyuki Shirasaka, Shoko Kobayashi, and Ikumi Tamai* . . . . . **1676**
- CYP2D6-CYP2C9 Protein-Protein Interactions and Isoform-Selective Effects on Substrate Binding and Catalysis. *Murali Subramanian, Michael Low, Charles W. Locuson, and Timothy S. Tracy* . . . . . **1682**
- Identification of New 2-Amino-3-methylimidazo[4,5-f]-quinoline Urinary Metabolites from  $\beta$ -Naphthoflavone-Treated Mice. *Vijaya M. Lakshmi, Fong-Fu Hsu, and Terry V. Zenser* . . . . . **1690**
- Complex Pharmacokinetic Behavior of Ezetimibe Depends on Abcc2, Abcc3, and Abcg2. *Dirk R. de Waart, Maria L. H. Vlaming, Cindy Kunne, Alfred H. Schinkel, and Ronald P. J. Oude Elferink* . . . . . **1698**
- The Importance of Heterogeneous Nuclear Ribonucleoprotein K on Cytochrome P450 2D2 Gene Regulation: Its Binding Is Reduced in Dark Agouti Rats. *Noriaki Sakai, Kentaro Q. Sakamoto, Shoichi Fujita, and Mayumi Ishizuka* . . . . . **1703**
- Selective Role of Sulfotransferase 2A1 (SULT2A1) in the N-Sulfoconjugation of Quinolone Drugs in Humans. *Laddawan Senggunprai, Kouichi Yoshinari, and Yasushi Yamazoe* . . . . . **1711**
- Vitreal Kinetics of Quinidine in Rabbits in the Presence of Topically Coadministered P-Glycoprotein Substrates/Modulators. *Soumyajit Majumdar, Ketan Hippalgaonkar, and Ramesh Srirangam* . . . . . **1718**
- Characterizing the Effects of Common UDP Glucuronosyltransferase (UGT) 1A6 and UGT1A1 Polymorphisms on *cis*- and *trans*-Resveratrol Glucuronidation. *Otito Frances Iwuchukwu, Jumoke Ajetunmobi, Din Ung, and Swati Nagar* . . . . . **1726**
- Cannabidiol-2',6'-Dimethyl Ether, a Cannabidiol Derivative, Is a Highly Potent and Selective 15-Lipoxygenase Inhibitor. *Shuso Takeda, Noriyuki Usami, Ikuo Yamamoto, and Kazuhito Watanabe* . . . . . **1733**
- Comparative Metabolism of  $^{14}\text{C}$ -Labeled Apixaban in Mice, Rats, Rabbits, Dogs, and Humans. *Donglu Zhang, Kan He, Nirmala Raghavan, Lifei Wang, James Mitroka, Brad D. Maxwell, Robert M. Knabb, Charles Frost, Alan Schuster, Feng Hao, Zheming Gu, W. Griffith Humphreys, and Scott J. Grossman* . . . . . **1738**
- Metabolite Profiling of Hydroxycinnamate Derivatives in Plasma and Urine after the Ingestion of Coffee by Humans: Identification of Biomarkers of Coffee Consumption. *Angélique Stalmach, William Mullen, Denis Barron, Kenichi Uchida, Takao Yokota, Christophe Cavin, Heike Steiling, Gary Williamson, and Alan Crozier* . . . . . **1749**
- Quantitative Analysis of UDP-Glucuronosyltransferase (UGT) 1A and UGT2B Expression Levels in Human Livers. *Takeshi Izukawa, Miki Nakajima, Ryoichi Fujiwara, Hiroyuki Yamanaka, Tatsuki Fukami, Masataka Takamiya, Yasuhiro Aoki, Shin-ichi Ikushiro, Toshiyuki Sakaki, and Tsuyoshi Yokoi* . . . . . **1759**
- Use of Human Microsomes and Deuterated Substrates: An Alternative Approach for the Identification of Novel Metabolites of Ketamine by Mass Spectrometry. *Sophie C. Turfus, Mark C. Parkin, David A. Cowan, John M. Halket, Norman W. Smith, Robin A. Braithwaite, Simon P. Elliot, Glyn B. Steventon, and Andrew T. Kicman* . . . . . **1769**
- Pharmacokinetics of Acetaminophen-Protein Adducts in Adults with Acetaminophen Overdose and Acute Liver Failure. *Laura P. James, Lynda Letzig, Pippa M. Simpson, Edmund Capparelli, Dean W. Roberts, Jack A. Hinson, Timothy J. Davern, and William M. Lee* . . . . . **1779**
- Characterization of Sulfoxxygenation and Structural Implications of Human Flavin-Containing Monooxygenase Isoform 2 (FMO2.1) Variants S195L and N413K. *Sharon K. Krueger, Marilyn C. Henderson, Lisbeth K. Siddens, Jonathan E. VanDyke, Abby D. Benninghoff, P. Andrew Karplus, Bjarte Furnes, Daniel Schlenk, and David E. Williams* . . . . . **1785**

 Supplemental material is available online at <http://dmd.aspetjournals.org>.

*About the cover:* The percentage of mRNA levels of each UGT isoform in sum of all UGT levels. See article by Izukawa et al. on page 1759 of this issue.